Novel Health Strategies team presented 26 studies at ISPOR 2016 Annual Meeting in Washington DC on market access strategy, pricing and health economic and outcomes research trends.

These studies were led by Novel Health team and are good examples of wide breadth and depth of our expertise.

NOVEL was also selected for a PODIUM session and nominated for TWO AWARDS.

In-person replays of all presentations are available upon request.

PCV16: TRENDS IN ER VISITS DUE TO HYPERKALEMIA IN THE UNITED STATES

PCV17: SYSTEMATIC REVIEW OF BURDEN OF HYPERKALEMIA DUE TO ANGIOTENSIN ENZYME CONVERTING INHIBITORS

PRM21: LATEST TRENDS IN DESIGN OF CLINICAL TRIALS FOR STROKE TREATMENT WITH STEM CELLS

RM191: LATEST TRENDS IN DESIGN OF CLINICAL TRIALS FOR REAL-WORLD HEALTH ECONOMIC EVIDENCE GENERATION

PRM180: LATEST TRENDS IN DESIGN OF PIVOTAL PHASE III CLINICAL TRIALS FOR HEMOPHILIA A AND B

PRM35: LATEST TRENDS IN DESIGN OF PIVOTAL CLINICAL TRIALS FOR HUNTINGTON'S DISEASE

PRM179: TRENDS IN DESIGN OF PIVOTAL PHASE III CLINICAL TRIALS FOR ALPHA 1 ANTI TRYPSIN DEFICIENCY DISORDER

PRM185: LATEST TRENDS IN DESIGN OF PIVOTAL PHASE III CLINICAL TRIALS FOR PERIPHERAL T-CELL LYMPHOMA

PRM186: TRENDS IN DESIGN OF PIVOTAL PHASE III CLINICAL TRIALS FOR CLUSTER HEADACHE DISORDER

PMD8: BAYESIAN NETWORK META-ANALYSIS ON PREVENTION OF STROKE FOR PATENT FORAMEN OVALE CLOSURE

PRM181: LATEST TRENDS IN DESIGN OF PIVOTAL PHASE III CLINICAL TRIALS FOR PARTIAL ONSET OF SEIZURES

PCN192: ANALYSIS OF ACCESS TO HARVONI FOR MEDICARE PATIENTS IN ALL FIFTY STATES IN THE US

PCN193: PATIENT ACCESS TO ORAL BREAKTHROUGH CANCER DRUGS IN THE UNITED STATES

PSY37: SYSTEMATIC REVIEW OF COST-EFFECTIVENESS ANALYSES OF ULTRA-ORPHAN THERAPIES

PGI33: HARVONI ACCESS AND UTILIZATION TRENDS IN FIFTY MEDICAID PROGRAMS IN THE UNITED STATES

PND67: TRENDS IN DESIGN, CONDUCT, AND OUTCOMES MEASURES FOR PATIENT REGISTRIES FOR MULTIPLE SCLEROSIS

PHP12: PRICE INCREASES FOR GENERICS IMPOSING NEW MARKET ACCESS CHALLENGE: INSIGHTS FROM ANALYSIS OF FORMULARY COVERAGE TRENDS FOR GENERICS

PHP132: ANALYSIS OF ESSENTIAL HEALTH BENEFIT BENCHMARK PLANS IN THE UNITED STATES

PCN40: SYSTEMATIC REVIEW OF DESIGN OF LATEST REAL-WORLD OBSERVATIONAL STUDIES IN MULTIPLE MYELOMA